Hardy Reed’s Novartis NVS Stock Holding History

Hardy Reed’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Sell	1,440 -36	-2%	-$5.4K	0.01%	235
2026 Q1	$225K	Buy	+1,476	New	+$226K	0.02%	228

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hardy Reed's NVS Position: Q2 2026 in Review

Hardy Reed reduced its Novartis (NVS) stake by 2.4% in Q2 2026, selling an estimated $5.4K and leaving 1,440 shares worth $226K. The position accounts for 0.01% of the portfolio, ranked #235.

Hardy Reed first reported a position in NVS in Q1 2026 and has held it in 2 quarters since. 1,623 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Hardy Reed held 1,440 shares of Novartis worth $226K as of Q2 2026.
Hardy Reed sold 36 Novartis shares in Q2 2026, an estimated $5.4K.
Novartis made up 0.01% of Hardy Reed's portfolio in Q2 2026, its #235 holding.
Hardy Reed first reported a position in Novartis in Q1 2026 and has held it in 2 quarters since.
1,623 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Hardy Reed's 13F filing for Q2 2026, filed 3 Aug 2026.